The University of Queensland has announced that Professor Chengzhong Yu, Senior Group Leader, Australian Institute for Bioengineering and Nanotechnology (AIBN) has been awarded a $402,115 grant to develop an improved nanoparticle delivery system that enhances the performance of messenger ribonucleic acid (mRNA) therapies. The new nanoparticle will be based [...]
Our new animation displays how Nuvec’s® unique spiky structure and large surface area allow it to efficiently load, protect and deliver multiple siRNA to a target cell through endocytosis. Once delivered to the cytoplasm, the siRNA binds to the RNA-inducing silencing complex (RISC) to cut and degrade the specific [...]
In our latest article, we look at how Nuvec® offers an alternative to current drug delivery approaches for small interfering RNA (siRNA). Not only is Nuvec® particularly suited to chemical modification, allowing the addition of target specific ligands to receptors on cancer cells, but it may offer the convenience of [...]
As a result of recently completed initial testing in vitro on loaded Nuvec® with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec® works to deliver multiple siRNA into the same cell. With siRNA increasingly being used in the development [...]
Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence of plasmid via controlled sonication. It evaluated the performance of controlled cavitation using different [...]
In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene therapy delivery platform in cancer treatment. Introducing exogenous genetic material to a cell alters [...]
N4 Pharma highlights the potential of Nuvec® as a gene therapy delivery platform by successfully completing a pre-clinical, in-vivo oncology study. The results reinforce the findings from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous (“i.v”) route of administration using [...]
N4 Pharma has successfully completed an in vivo confirmatory oncology study which reinforces the results from an earlier pilot study designed to test the ability to use a monodispersed Nuvec® formulation in an intravenous ("i.v") route of administration using a DNA plasmid (pDNA) encoding TNF alpha, to assess the [...]
"The development of smart drug delivery systems will improve drug efficacy, reduce costs, and improve storage, and ultimately lead to better treatments for the patient.” N4 Pharma’s CEO, Nigel Theobald, is featured in this month’s BioPharm International magazine talking about some of the next generation technologies that could be [...]
Our partners at Medicines Discovery Catapult gave a presentation on behalf of N4 Pharma at the European Laboratory Research & Innovation Group’s (ELRIG) UK meeting in Liverpool this week. The full poster, titled ‘Investigation of Nuvec® particles for effective gene delivery’, can be viewed by clicking here. We're also [...]
